LI-RADS 2018版治疗反应算法在细胞外对比剂增强MRI上评估经动脉化疗栓塞治疗肝细胞癌的诊断效能及辅助征象的附加价值
回顾性纳入2019年1月至2023年6月接受TACE后行肝脏手术的HCC患者61例79个病灶,比较LI-RADS v2018 TRA与加入辅助征象的改良LR-TR算法预测病理肿瘤存活的诊断效能。改良LR-TR预测非完全病理坏死的敏感度88%(50/57)显著高于LR-TR的75%(43/57)(P=0.016),特异度77%(17/22)与82%(18/22)无差异(P=1.000)。两种算法在cTACE与DEB-TACE亚组间预测存活肿瘤的敏感度无显著差异。
要点
- 改良LR-TR在LR-TR基础上加入弥散受限和T2WI中等高信号两个辅助征象。
- 预测非完全病理坏死,改良LR-TR敏感度88%(50/57)高于LR-TR的75%(43/57),P=0.016。
- 两算法特异度无差异(77% vs 82%,P=1.000),读者间一致性均为中等(k=0.50与k=0.42)。
核心结论
- 在细胞外对比剂增强MRI上,将辅助征象应用于LI-RADS v2018 TRA可提高预测TACE治疗肝细胞癌病理肿瘤存活的敏感度,特异度无显著差异。
研究设计与样本
- 回顾性研究,纳入2019年1月至2023年6月接受TACE后行肝脏手术且TACE前后均有增强MRI的HCC患者61例(平均年龄59岁±10,男47例)共79个病灶(57个病理存活)。
关键影像表现/征象
- 辅助征象包括弥散受限和T2加权成像中等高信号。
- 以手术病理为参考标准,病灶分为完全病理坏死(100%,CPN)和非完全病理坏死(<100%,non-CPN)。
诊断标准与关键数值
- 预测非完全病理坏死,LR-TR存活类别的敏感度75%(43/57)、特异度82%(18/22)。
- 预测非完全病理坏死,改良LR-TR存活类别的敏感度88%(50/57)、特异度77%(17/22)。
- 改良LR-TR敏感度显著高于LR-TR(P=0.016),特异度无差异(P=1.000)。
- LR-TR与改良LR-TR类别读者间一致性均为中等(k=0.50,95%CI 0.33-0.67;k=0.42,95%CI 0.20-0.63)。
- cTACE与DEB-TACE亚组间,LR-TR和改良LR-TR预测存活肿瘤的敏感度无显著差异(cTACE:76%、89% vs DEB-TACE:73%、82%)。
临床应用与阅片要点
- 在细胞外对比剂增强MRI上评估TACE治疗后HCC时,可参考在LR-TR基础上加入弥散受限和T2WI中等高信号两个辅助征象的改良LR-TR算法。
- 改良LR-TR提高预测病理肿瘤存活的敏感度,特异度无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm (TRA) (LI-RADS TRA) is used for assessing response of HCC to locoregional therapy (LRT), however, the value of ancillary features (AFs) for TACE-treated HCCs has not been extensively investigated on extracellular agent MRI (ECA-MRI).
PURPOSE: To evaluate the diagnostic performance of LI-RADS v2018 TRA on ECA-MRI for HCC treated with transarterial chemoembolization (TACE) and the value of ancillary features.
METHODS: This retrospective study included patients who underwent TACE for HCC and then followed by hepatic surgery between January 2019 and June 2023 with both pre- and post-TACE contrast-enhanced MRI available. Two radiologists independently evaluated the post-treated lesions on MRI using LI-RADS treatment response (TR) (LR-TR) algorithm and modified LR-TR (mLR-TR) algorithm in which ancillary features (restricted diffusion and intermediate T2-weighted hyperintensity) were added, respectively. Lesions were categorized as complete pathologic necrosis (100%, CPN) and non-complete pathologic necrosis (< 100%, non-CPN) on the basis of surgical pathology. The diagnostic performance in predicting viable and non-viable tumors based on LR-TR and mLR-TR algorithms was compared using the McNemar test. Interreader agreement was calculated by using Cohen's weighted and unweighted κ.
RESULTS: A total of 61 patients [mean age 59 years ± 10 (standard deviation); 47 men] with 79 lesions (57 pathologically viable) were included. For non-CPN prediction, the sensitivity, specificity of LR-TR viable and mLR-TR viable category were 75% (43 of 57), 82% (18 of 22) and 88% (50 of 57), 77% (17 of 22), respectively, the sensitivity of mLR-TR was significantly higher than that of LR-TR (P = 0.016) without difference in specificity (P = 1.000). Interreader agreement for LR-TR and mLR-TR category was moderate (k = 0.50, 95% confidence interval 0.33, 0.67, k = 0.42, 95% confidence interval 0.20, 0.63). The sensitivity of both LR-TR and mLR-TR algorithms in predicting viable tumors between conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) did not have significant difference (cTACE: 76%, 89% vs. DEB-TACE: 73%, 82%).
CONCLUSIONS: On ECA-MRI, applying ancillary features to LI-RADS v2018 TRA can improve the sensitivity in predicting pathologic tumor viability in patients treated with TACE for hepatocellular carcinoma with no significant difference in specificity.
引用
- Wang D, Zhang Y, Lyu R, et al. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features. Abdom Radiol (NY). 2024. PMID: 38605217. doi:10.1007/s00261-024-04275-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。